vivoPharm is Latest Research Service Organization to Join Repositive Cancer Model Network
Repositive has announced today that vivoPharm has joined its global network of CRO partners. With this new partnership, Repositive is continuing to grow its global reach and cancer model search capabilities to support more biopharma customers in sourcing the right preclinical cancer models for their research.
“We are excited to see how quickly our preclinical cancer model network is expanding to support Repositive’s recent pivot towards our Cancer Model Scout search service. These new partnerships are helping to uniquely position us to perform even the most complex of model searches for our biopharma customers, especially those looking for very specific or hard-to-find models.” – said Catherine McDermott, CEO of Repositive.
Repositive’s core offering is a subscription package with a specialist and cost-effective cancer model search service, the Cancer Model Scout (CMS), which connects cancer researchers to the right preclinical models and CROs, based on individual study requirements. In just 2-4 weeks, Repositive’s team of expert bioinformaticians can conduct a detailed cancer model search across their extended CRO network and compile a comprehensive list of models matches, complete with a bioinformatics report of methods. Cancer Model Scout searches are part of a tailored subscription package and include access to Repositive’s beta Cancer Model Platform, an online directory of over 8000 preclinical cancer models. Learn more about Repositive’s cancer models, data and services here.
Founded in 2003, vivoPharm, a Vyant Bio company, offers integrated drug discovery services in cancer and other disease areas to global pharmaceutical and biotechnology companies and academic research centers. vivoPharm is a leading provider of syngeneic and xenograft orthotopic and metastases tumour models. vivoPharm also offers a wide range of cell-based assays, including functional human iPSC-derived organoid models, toxicology testing and GLP-compliant bioanalytical analysis. vivoPharm specialises in conducting studies tailored to guide drug development, starting from compound libraries and ending with a comprehensive set of data and reports, as needed for Investigational New Drug (IND) filings.
“We look forward to expanding access to our extensive database of tumor models and oncology services through this partnership. It is a great fit for our mission to serve the drug discovery community, with a focus on supporting the discovery and development of new therapeutic agents.”, said Dr Ralf Brandt, President of Discovery and Early Development Services at vivoPharm.